{"product_id":"novel-drug-reconstitution-systems-market-2021-2030-distribution-by-type-of-container-cartridge-infusion-bag-and-prefilled-syringe-fabrication-material-glass-and-plastic-physical-state-of-drug-in-syringe-and-cartridge-liquid-powder-liquid-liq","title":"Novel Drug Reconstitution Systems Market, 2021-2030 Distribution by Type of Container (Cartridge, Infusion Bag and Prefilled Syringe), Fabrication Material (Glass and Plastic), Physical State of Drug in Syringe and Cartridge (Liquid \/ Powder, Liquid \/ Liq","description":"\u003cp\u003eNovel Drug Reconstitution Systems Market, 2021-2030 Distribution by Type of Container (Cartridge, Infusion Bag and Prefilled Syringe), Fabrication Material (Glass and Plastic), Physical State of Drug in Syringe and Cartridge (Liquid \/ Powder, Liquid \/ Liquid), Physical State of Drug in Infusion Bag (Liquid Mixture, Frozen Mixture), Volume of Container (\u0026lt;1 mL, 1-2.5 mL, 2.5-5 mL, \u0026gt;5 mL for prefilled syringe and cartridge; \u0026lt;250 mL, 250-500 mL, 500-1,000 mL, \u0026gt;1,000 mL for infusion bag), Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2021-2030\u003c\/p\u003e\n\n\n\n\u003cp\u003eOver the last few years, numerous biologics and small molecule drugs have made their way to the market. Most of these biologic products are not stable as liquid formulations, and tend to lose efficacy with alterations in their pharmacokinetic and pharmacodynamic properties, thereby, making it difficult to preserve them for longer period of time. In order to achieve longer shelf life, lyophilization has emerged as the preferred choice for making dry biopharmaceutical formulations. In fact, around 30% of the FDA approved parenteral drugs are in lyophilized form. Since 2014, the FDA had approved more than 20 applications for lyophilized new drugs.  Evidently, this method of producing stabilized formulations has witnessed widespread adoption and the affiliated market opportunity is estimated to be USD 3 billion. The increased adoption of such drugs has led to the rise in demand for reconstitution systems that allow proper mixing of lyophilized drug with the diluent and administration of required dose. The traditional reconstitution methods involve manual extraction and transfer of diluent into the vials containing the lyophilized product, using syringe and transfer needle. Given the large number of steps involved and multiple containers, this method is associated with the risk of medication errors and needle-stick injuries. In addition, the complexity associated with these conventional systems restricts the injection of lyophilized drugs only by the healthcare workers within the confined area of healthcare facilities.\u003c\/p\u003e\n\n\n\n\u003cp\u003eThe existing challenges in the conventional reconstitution method have prompted the pharmaceutical industry to develop advanced reconstitution devices, which allow the patients and caregivers to administer drugs without healthcare provider’s intervention. These systems contain premeasured dose of drug and diluent, which essentially reduces the chances of dosing errors and needle-stick injuries. Moreover, these advanced systems enhance the portability, efficiency and optimum delivery of the lyophilized drugs and have the potential to reduce the number of steps significantly, which enable the dilution and reconstitution at the time of delivery. Owing to their multiple benefits, various pharmaceutical companies are considering these systems for lifecycle management of their drugs in order to enhance the provision of healthcare. Further, it is worth mentioning that over 1,800 patent applications have been filed \/ granted for reconstitution systems and affiliated technologies. We believe that such efforts are likely to drive growth in this market over the coming years.\u003c\/p\u003e \n\n\n\n\u003cp\u003eThe ‘Novel Drug Reconstitution Systems Market  by Type of Container (Cartridge, Infusion Bag and Prefilled Syringe), Fabrication Material (Glass and Plastic), Physical State of Drug in Syringe and Cartridge (Liquid \/ Powder, Liquid \/ Liquid), Physical State of Drug in Infusion Bag (Liquid Mixture, Frozen Mixture), Volume of Container (\u0026lt;1 mL, 1-2.5 mL, 2.5-5 mL, \u0026gt;5 mL for prefilled syringe and cartridge; \u0026lt;250 mL, 250-500 mL, 500-1,000 mL, \u0026gt;1,000 mL for infusion bag), Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2021-2030’ report features an extensive study on the current and future potential of novel drug reconstitution systems, being developed in order to ease the storage and administration of lyophilized drugs, thereby maintaining stability and shelf-life. In addition, it features an elaborate discussion on the likely opportunity for the players engaged in this domain, over the next decade. Amongst other elements, the report includes:\u003c\/p\u003e\n\n\n\n\u003cp\u003eA detailed assessment of the current market landscape of novel drug reconstitution systems, providing information on the type of device (prefilled syringe, cartridge, infusion bags), type of chamber (dual chamber, multi chamber), physical state of drug (lyophilized, liquid), container fabrication material (glass, plastic), device usability (single use, multi-use), and volume of container. In addition, the chapter includes details related to novel drug reconstitution system manufacturers, along with information on their year of establishment, company size, location of headquarters and key players (in terms of number of products manufactured).\u003c\/p\u003e\n\n\n\n\u003cp\u003eA detailed landscape of the reconstitution devices and systems featuring information on type of container or device, volume of primary container, physical state of drug, device usability and provision for self-administration. In addition, the chapter includes details related to the manufacturers, along with information on their year of establishment, company size and location of headquarters.\u003c\/p\u003e\n\n\n\n\u003cp\u003eElaborate profiles of prominent players engaged in this domain. Each profile includes a brief overview of the company, details related to its financial information (if available), information on product portfolio, recent developments and an informed future outlook.\u003c\/p\u003e\n\n\n\n\u003cp\u003eA detailed analysis on the trends in packaging of over 350 drug products (including both biologics and small molecule drugs) that were approved by the FDA between 2014 and H1 2021, featuring an assessment of the packaging requirements of various container-closure systems based on several parameters, such as year of approval of drug, type of molecule (small molecule, biologic), type of biologic (allogeneic cell therapy, autologous cell therapy, fusion proteins, hormones, interferons, monoclonal antibodies, recombinant enzymes, recombinant protein and viral cell therapy), type of primary packaging container used (vials, pouches \/ packets, bottles, IV \/ sealed bags, prefilled syringes \/ pen , tubes, cartridge, blister packaging, others), type of packaging material(s) used for manufacturing primary container, type of closure used (cap \/ needle shield, seal, plunger, stopper and others), type of packaging material(s) used for manufacturing closures, dosage form, route of administration, holding temperature. In addition, the chapter provides information on the developers of the aforementioned drugs and an analysis based on year of establishment, company size, location of headquarters and leading drug developers (in terms of number of  drugs approved).\u003c\/p\u003e\n\n\n\n\u003cp\u003eAn insightful analysis of the patents filed \/ granted for novel drug reconstitution systems, since 2011, taking into consideration various relevant parameters, such as type of patent, publication year, geographical location, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted \/ filed in the given time period), patent characteristics and geography. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis.\u003c\/p\u003e\n\n\n\n\u003cp\u003eA competitiveness analysis of novel drug reconstitution system manufacturers based on various relevant parameters, such as supplier power (in terms of experience \/ expertise of the manufacturer) and key product specifications (number of systems, type of systems, type of drugs and number of chambers).\u003c\/p\u003e\n\n\n\n\u003cp\u003eAn in-depth analysis of recent events (summits \/ forums \/ conferences \/ annual meetings) that were organized for stakeholders in this domain, highlighting the evolution of discussion topics related to novel drug reconstitution systems. The analysis also provides details on type of event, regional distribution, emerging agendas, popular organizers, active industry and non-industry players, and a schematic mapping of upcoming events.\u003c\/p\u003e\n\n\n\n\u003cp\u003eA discussion on affiliated trends, key drivers and challenges, under a SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall novel drug reconstitution systems market.\u003c\/p\u003e\n\n\n\n\u003cp\u003eAn in-depth analysis to estimate the current and future demand for various novel drug reconstitution systems, including cartridges, infusion bags and prefilled syringes.\u003c\/p\u003e  \n\n\n\n\u003cp\u003eAn elaborate discussion on emerging trends that are likely to have an impact on the future adoption of novel drug reconstitution systems. It presents a Harvey ball analysis, highlighting the relative effect of each trend on the adoption of novel drug reconstitution systems including dual chamber systems.\u003c\/p\u003e\n\n\n\n\u003cp\u003eOne of the key objectives of the report was to estimate the existing market size and the future opportunity for novel drug reconstitution systems, over the next decade. Based on various parameters, such as target consumer segments, likely adoption rates and expected prices of such products, we have provided informed estimates on the evolution of the market for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] type of reconstitution system (prefilled syringe \/ cartridge \/ infusion bag), [B] physical state of drug (liquid \/ powder, liquid \/ liquid for prefilled syringes and cartridges; liquid mixture and frozen mixture for infusion bags), [C] type of fabrication material (glass, plastic \/ type of plastic for infusion bags), [D] volume of container (\u0026lt;1 mL, 1-2.5 mL, 2.5-5 mL and \u0026gt;5 mL for prefilled syringes and cartridges; 0-250 mL, 250-500 mL, 500-1,000 mL and \u0026gt;1,000 mL for infusion bags), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.\u003c\/p\u003e\n\n\n\n\u003cp\u003eAll actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.\u003c\/p\u003e\n\n\n\n\u003cp\u003eRESEARCH METHODOLOGY\u003c\/p\u003e\n\n\u003cp\u003eThe data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. The information is primarily useful for us to draw out our opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been validated from multiple sources of information.\u003c\/p\u003e\n\n\n\n\u003cp\u003eThe secondary sources of information include:\u003c\/p\u003e\n\n\u003cp\u003eAnnual reports\u003c\/p\u003e\n\n\u003cp\u003eInvestor presentations\u003c\/p\u003e\n\n\u003cp\u003eSEC filings\u003c\/p\u003e\n\n\u003cp\u003eIndustry databases\u003c\/p\u003e\n\n\u003cp\u003eNews releases from company websites\u003c\/p\u003e\n\n\u003cp\u003eGovernment policy documents\u003c\/p\u003e\n\n\u003cp\u003eIndustry analysts’ views\u003c\/p\u003e\n\n\n\n\u003cp\u003eWhile the focus has been on forecasting the market till 2030, the report also provides our independent views on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.\u003c\/p\u003e\n\n\n\n\u003cp\u003eKEY QUESTIONS ANSWERED\u003c\/p\u003e\n\n\u003cp\u003eWho are the key players engaged in the development of novel drug reconstitution systems?\u003c\/p\u003e\n\n\u003cp\u003eWhat is the relative competitiveness of different novel drug reconstitution system manufacturers?\u003c\/p\u003e\n\n\u003cp\u003eWhat is the packaging trend in terms of container and closure for the drugs approved since 2014?\u003c\/p\u003e\n\n\u003cp\u003eWho are the leading players focused on the development of lyophilized drugs?\u003c\/p\u003e\n\n\u003cp\u003eWhat is the focus area of various conferences conducted in this domain?\u003c\/p\u003e\n\n\u003cp\u003eHow has the intellectual property landscape in this domain evolved over the years?\u003c\/p\u003e\n\n\u003cp\u003eWhat are the emerging trends related to pharmaceutical packaging?\u003c\/p\u003e\n\n\u003cp\u003eWhat are the key agenda items being discussed in various global events \/ conferences held in this domain?\u003c\/p\u003e\n\n\u003cp\u003eHow is the current and future market opportunity, likely to be distributed across key market segments?\u003c\/p\u003e\t\t\t\n\n\n\n\u003cp\u003eCHAPTER OUTLINES\u003c\/p\u003e\n\n\u003cp\u003eChapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the novel drug reconstitution systems market and its likely evolution in the short-mid to long term.\u003c\/p\u003e\n\n\n\n\u003cp\u003eChapter 3 provides a general introduction to novel drug reconstitution systems. In this chapter, we have briefly discussed the key considerations in reconstitution and the factors affecting reconstitution of drugs. The chapter also discusses the process of lyophilization of pharmaceuticals and need for reconstitution systems. In addition, it provides information on dual chamber systems and the benefits offered by these systems.\u003c\/p\u003e\n\n\n\n\u003cp\u003eChapter 4 presents an overview of the current market landscape of novel drug reconstitution systems, along with information on the type of device (prefilled syringe, cartridge, infusion bags), type of chamber (dual chamber, multi chamber), physical state of drug (lyophilized, liquid), container fabrication material (glass, plastic), device usability (single use, multi-use), and volume of container. It also includes a detailed analysis based on the year of establishment, company size (in terms of employee count), region and location of headquarters. In addition, the chapter provides information on the novel drug reconstitution system manufacturers, while highlighting the leading players in this domain.\u003c\/p\u003e\n\n\n\n\u003cp\u003eChapter 5 presents an overview of the current market landscape of other reconstitution devices and systems (one step reconstitution systems and conventional reconstitution devices), along with information on the type of primary container, volume of primary container, physical state of drug, device usability and provision for self-administration. The chapter also provides information on the manufacturers of other reconstitution systems, along with analysis based on their year of establishment, company size, location of headquarters and leading players (in terms of number of products manufactured).\u003c\/p\u003e\n\n\n\n\u003cp\u003eChapter 6 includes profiles of the key players engaged in the development of novel drug reconstitution systems (shortlisted on the basis of the company size and the number of products in the pipeline). Each profile features a brief overview of the company, its financial information (if available), details on its product portfolio, recent developments and an informed future outlook.\u003c\/p\u003e\n\n\n\n\u003cp\u003eChapter 7 provides a detailed review of the packaging trends of over 350 product candidates (biologics and small molecule drugs) that were approved by the FDA between 2014 and H1 2021, including an analysis of the packaging requirements based on several relevant parameters, such as approval year of drug, type of molecule (small molecule, biologic), type of biologic (allogeneic cell therapy, autologous cell therapy, fusion proteins, hormones, interferons, monoclonal antibodies, recombinant enzymes, recombinant protein and viral cell therapy), type of primary packaging container used (vials, pouches \/ packets, bottles, IV \/ sealed bags, prefilled syringes \/ pen , tubes, cartridge, blister packaging, others), most popular packaging material(s) used for primary containers, type of primary packaging closure used (cap \/ needle shield, seal, plunger, stopper and others), most popular packaging material(s) used for manufacturing closures, dosage form, route of administration, holding temperature. Further, the chapter provides information on the developers of the approved drugs, along with information on their year of establishment, company size, location of headquarters and most active players (in terms of number of small molecule drugs and number and type of biologics approved).\u003c\/p\u003e\n\n\n\n\u003cp\u003eChapter 8 features an in-depth analysis of the patents that have been filed \/ granted for the novel drug reconstitution systems, since 2011. The analysis also highlights the key trends associated with the patents, such as the type of patent  (granted patent, patent application and others), publication year, application year, geographical location, CPC symbols, emerging focus areas of the patents, type of organization and leading players (in terms of number of patents granted \/ filed). In addition, it includes detailed patent benchmarking and valuation analysis based on patent characteristics.\u003c\/p\u003e \n\n\n\n\u003cp\u003eChapter 9 provides a competitiveness analysis of novel drug reconstitution system manufacturers that we came across during our research, based on supplier strength (in terms of experience \/ expertise of the manufacturer) and key product specifications (number of systems, type of systems, type of drugs and number of chambers).\u003c\/p\u003e\n\n\n\n\u003cp\u003eChapter 10 provides an analysis of recent events (summits \/ forums \/ conferences \/ workshops) related to novel drug reconstitution systems that were organized \/ planned. It features an analysis based on the year of occurrence of event, event platform, type of event, regional distribution, emerging agendas \/ key focus areas, most active event organizers, most active event speakers and geographical mapping of the upcoming events.\u003c\/p\u003e\n\n\n\n\u003cp\u003eChapter 11 provides information on the affiliated trends, key drivers and challenges associated with novel drug reconstitution systems, under a reliable SWOT framework. The chapter includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall novel drug reconstitution systems market.\u003c\/p\u003e\n\n\n\n\u003cp\u003eChapter 12 features a detailed analysis on the current and future demand for novel drug reconstitution systems. We have provided inputs on the likely demand for these systems across the type of reconstitution system (prefilled syringe \/ cartridge \/ infusion bag), physical state of drug (liquid \/ powder, liquid \/ liquid for prefilled syringes and cartridges; liquid mixture and frozen mixture for infusion bags), type of fabrication material (glass, plastic \/ type of plastic for infusion bags), volume of container (\u0026lt;1 mL, 1-2.5 mL, 2.5-5 mL and \u0026gt;5 mL for prefilled syringes and cartridges; 0-250 mL, 250-500 mL, 500-1,000 mL and \u0026gt;1,000 mL for infusion bags) geography (North America, Europe, Asia-Pacific, Latin America and Middle East and Africa) for the period, 2021-2030.\u003c\/p\u003e \n\n\n\n\u003cp\u003eChapter 13 features a detailed market forecast of the likely growth of novel drug reconstitution systems, till the year 2030. We have generated insights on the likely distribution of the current and forecasted opportunity across the type of reconstitution system (prefilled syringe \/ cartridge \/ infusion bag), physical state of drug (liquid \/ powder, liquid \/ liquid for prefilled syringes and cartridges; liquid mixture and frozen mixture for infusion bags), type of fabrication material (glass, plastic \/ type of plastic for infusion bags), volume of container (\u0026lt;1 mL, 1-2.5 mL, 2.5-5 mL and \u0026gt;5 mL for prefilled syringes and cartridges; 0-250 mL, 250-500 mL, 500-1,000 mL and \u0026gt;1,000 mL for infusion bags), and key geographical regions (North America, Europe, Asia-Pacific, Latin America and Middle East and Africa).\u003c\/p\u003e\n\n\n\n\u003cp\u003eChapter 14 provides information on the upcoming emerging trends (including preference for self-medication of drugs, shift towards more flexible packaging, focus on personalized therapies, integrating dual chamber systems with other platforms, and increase in the initiatives undertaken by industry stakeholders) that are likely to have an impact on the future adoption of novel drug reconstitution systems. It also presents a Harvey ball analysis, highlighting the relative impact of each trend on the adoption of novel drug reconstitution systems including dual chamber systems.\u003c\/p\u003e\n\n\n\n\u003cp\u003eChapter 15 is a summary of the overall report, presenting insights on the contemporary market trends and the likely evolution of the novel drug reconstitution systems market.\u003c\/p\u003e\n\n\n\n\u003cp\u003eChapter 16 is an appendix, that contains tabulated data and numbers for all the figures provided in the report.\u003c\/p\u003e\n\n\n\n\u003cp\u003eChapter 17 is an appendix, that contains the list of companies and organizations mentioned in the report.\u003c\/p\u003e\n\n\n\n\u003cp\u003eLIST OF COMPANIES AND ORGANIZATIONS\u003c\/p\u003e\n\n\n\n\u003cp\u003eThe following companies \/ institutes \/ government bodies and organizations have been mentioned in this report.\u003c\/p\u003e\n\n\n\n\u003cp\u003e1.\t\t3M Innovative Properties\u003c\/p\u003e\n\n\u003cp\u003e2.\t \tAbbVie\u003c\/p\u003e\n\n\u003cp\u003e3.\t \tAblynx\u003c\/p\u003e\n\n\u003cp\u003e4.\t \tAcacia Pharma\u003c\/p\u003e\n\n\u003cp\u003e5.\t \tAcadia Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e6.\t \tAcelRx Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e7.\t \tAchaogen\u003c\/p\u003e\n\n\u003cp\u003e8.\t \tAcorda Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e9.\t \tActelion Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e10.\t \tADC Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e11.\t \tADIENNE\u003c\/p\u003e\n\n\u003cp\u003e12.\t \tAdvanced Accelerator Applications (AAA)\u003c\/p\u003e\n\n\u003cp\u003e13.\t \tAdvoCare Medical\u003c\/p\u003e\n\n\u003cp\u003e14.\t \tAerie Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e15.\t \tAgios Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e16.\t \tAguettant\u003c\/p\u003e\n\n\u003cp\u003e17.\t \tAkaRx (acquired by Eisai)\u003c\/p\u003e\n\n\u003cp\u003e18.\t \tAkcea Therapeutics (acquired by Ionis Pharmaceuticals)\u003c\/p\u003e\n\n\u003cp\u003e19.\t \tAlcon Laboratories\u003c\/p\u003e\n\n\u003cp\u003e20.\t \tAlexion Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e21.\t \tAlkermes\u003c\/p\u003e\n\n\u003cp\u003e22.\t \tAllergan\u003c\/p\u003e\n\n\u003cp\u003e23.\t \tAlmirall\u003c\/p\u003e\n\n\u003cp\u003e24.\t \tAlnylam Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e25.\t \tAMAG Pharmaceuticals (acquired by Covis Pharma)\u003c\/p\u003e\n\n\u003cp\u003e26.\t \tAmgen\u003c\/p\u003e\n\n\u003cp\u003e27.\t \tAmivas\u003c\/p\u003e\n\n\u003cp\u003e28.\t \tAmphastar Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e29.\t \tAmsino\u003c\/p\u003e\n\n\u003cp\u003e30.\t \tAnacor Pharmaceuticals (acquired by Pfizer)\u003c\/p\u003e\n\n\u003cp\u003e31.\t \tAntares Pharma\u003c\/p\u003e\n\n\u003cp\u003e32.\t \tApellis Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e33.\t \tAquestive Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e34.\t \tARaymond\u003c\/p\u003e\n\n\u003cp\u003e35.\t \tArdelyx\u003c\/p\u003e\n\n\u003cp\u003e36.\t \tARIAD Pharmaceuticals (acquired by Takeda)\u003c\/p\u003e\n\n\u003cp\u003e37.\t \tArray BioPharma (acquired by Takeda)\u003c\/p\u003e\n\n\u003cp\u003e38.\t \tArte\u003c\/p\u003e\n\n\u003cp\u003e39.\t \tAstellas Pharma\u003c\/p\u003e\n\n\u003cp\u003e40.\t \tAstraZeneca\u003c\/p\u003e\n\n\u003cp\u003e41.\t \tAurinia Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e42.\t \tAVEO Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e43.\t \tB. Braun\u003c\/p\u003e\n\n\u003cp\u003e44.\t \tBausch \u0026amp; Lomb\u003c\/p\u003e\n\n\u003cp\u003e45.\t \tBausch Health Companies (formerly Valeant Pharmaceuticals)\u003c\/p\u003e\n\n\u003cp\u003e46.\t            Baxter\u003c\/p\u003e\n\n\u003cp\u003e47.\t \tBayer Healthcare\u003c\/p\u003e\n\n\u003cp\u003e48.\t \tBecton Dickinson (BD)\u003c\/p\u003e\n\n\u003cp\u003e49.\t \tBeiGene\u003c\/p\u003e\n\n\u003cp\u003e50.\t \tBiocorp\u003c\/p\u003e\n\n\u003cp\u003e51.\t \tBioCryst Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e52.\t \tBiogen\u003c\/p\u003e\n\n\u003cp\u003e53.\t \tBiohaven Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e54.\t \tBioMarin Pharmaceutical\u003c\/p\u003e\n\n\u003cp\u003e55.\t \tBioprojet Pharma\u003c\/p\u003e\n\n\u003cp\u003e56.\t \tBloodWorks\u003c\/p\u003e\n\n\u003cp\u003e57.\t \tBlue Earth\u003c\/p\u003e\n\n\u003cp\u003e58.\t \tBlueprint Medicines\u003c\/p\u003e\n\n\u003cp\u003e59.\t \tBoehringer Ingelheim\u003c\/p\u003e\n\n\u003cp\u003e60.\t \tBracco Diagnostics\u003c\/p\u003e\n\n\u003cp\u003e61.\t \tBraintree Laboratories  (acquired by Sebela Pharmaceuticals )\u003c\/p\u003e\n\n\u003cp\u003e62.\t \tBristol Myers Squibb\u003c\/p\u003e\n\n\u003cp\u003e63.\t \tCassiopea\u003c\/p\u003e\n\n\u003cp\u003e64.\t \tCatalyst Pharmaceuticals\u003c\/p\u003e \n\n\u003cp\u003e65.\t \tCelgene\u003c\/p\u003e\n\n\u003cp\u003e66.\t \tCelltrion\u003c\/p\u003e \n\n\u003cp\u003e67.\t \tChelsea Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e68.\t \tChemo Research\u003c\/p\u003e\n\n\u003cp\u003e69.\t \tChiesi USA\u003c\/p\u003e\n\n\u003cp\u003e70.\t \tCleveland Cord Blood Center (CCBC)\u003c\/p\u003e\n\n\u003cp\u003e71.\t \tCLINUVEL\u003c\/p\u003e\n\n\u003cp\u003e72.\t \tClovis Oncology\u003c\/p\u003e\n\n\u003cp\u003e73.\t \tCosmo Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e74.\t \tCredence Medsystems\u003c\/p\u003e\n\n\u003cp\u003e75.\t \tCubist Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e76.\t \tCurium\u003c\/p\u003e\n\n\u003cp\u003e77.\t \tDaiichi Sankyo\u003c\/p\u003e\n\n\u003cp\u003e78.\t \tDebiotech\u003c\/p\u003e\n\n\u003cp\u003e79.\t \tDeciphera Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e80.\t \tDr. Reddy's Laboratories\u003c\/p\u003e\n\n\u003cp\u003e81.\t \tDuoject\u003c\/p\u003e\n\n\u003cp\u003e82.\t \tDurata Therapeutics (acquired by Actavis)\u003c\/p\u003e\n\n\u003cp\u003e83.\t \tDutch Ophthalmic Research Center\u003c\/p\u003e\n\n\u003cp\u003e84.\t \tEiger BioPharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e85.\t \tEisai\u003c\/p\u003e\n\n\u003cp\u003e86.\t \tEli Lilly\u003c\/p\u003e\n\n\u003cp\u003e87.\t \tElusys Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e88.\t \tEMD Serono\u003c\/p\u003e\n\n\u003cp\u003e89.\t \tEnable Injections\u003c\/p\u003e\n\n\u003cp\u003e90.\t \tEpizyme\u003c\/p\u003e\n\n\u003cp\u003e91.\t \tEquashield\u003c\/p\u003e\n\n\u003cp\u003e92.\t \tEsperion Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e93.\t \tEvolus\u003c\/p\u003e\n\n\u003cp\u003e94.\t \tExEm Foam\u003c\/p\u003e\n\n\u003cp\u003e95.\t \tEyePoint Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e96.\t \tFerrer\u003c\/p\u003e\n\n\u003cp\u003e97.\t \tFresenius Kabi\u003c\/p\u003e\n\n\u003cp\u003e98.\t \tG1 Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e99.\t \tGalderma\u003c\/p\u003e\n\n\u003cp\u003e100.\tGenentech\u003c\/p\u003e\n\n\u003cp\u003e101.\tGerresheimer\u003c\/p\u003e\n\n\u003cp\u003e102.\tGilead Sciences\u003c\/p\u003e\n\n\u003cp\u003e103.\tGlaxoSmithKline\u003c\/p\u003e\n\n\u003cp\u003e104.\tGlobal Blood Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e105.\tGreenwich Biosciences\u003c\/p\u003e\n\n\u003cp\u003e106.\tGrifols\u003c\/p\u003e\n\n\u003cp\u003e107.\tHaemopharm\u003c\/p\u003e\n\n\u003cp\u003e108.\tHarmony Biosciences\u003c\/p\u003e\n\n\u003cp\u003e109.\tHelapet\u003c\/p\u003e\n\n\u003cp\u003e110.\tHelsinn Healthcare\u003c\/p\u003e\n\n\u003cp\u003e111.\tHemedis\u003c\/p\u003e\n\n\u003cp\u003e112.\tHorizon Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e113.\tICU Medical\u003c\/p\u003e\n\n\u003cp\u003e114.\tIDEO\u003c\/p\u003e\n\n\u003cp\u003e115.\tiHealthNet\u003c\/p\u003e\n\n\u003cp\u003e116.\tImmunomedics (acquired by Gilead Sciences)\u003c\/p\u003e\n\n\u003cp\u003e117.\tIncyte\u003c\/p\u003e\n\n\u003cp\u003e118.\tInsmed\u003c\/p\u003e\n\n\u003cp\u003e119.\tIntegrity Bio\u003c\/p\u003e\n\n\u003cp\u003e120.\tIntercept Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e121.\tIntra-Cellular Therapies\u003c\/p\u003e\n\n\u003cp\u003e122.\tIonis Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e123.\tIronwood Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e124.\tITF Pharma\u003c\/p\u003e\n\n\u003cp\u003e125.\tJanssen Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e126.\tJazz Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e127.\tJW Chemi Town\u003c\/p\u003e\n\n\u003cp\u003e128.\tKAI Pharmaceuticals (acquired by Amgen)\u003c\/p\u003e\n\n\u003cp\u003e129.\tKapsam\u003c\/p\u003e\n\n\u003cp\u003e130.\tKaryopharm Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e131.\tKemPharm\u003c\/p\u003e\n\n\u003cp\u003e132.\tKite Pharma\u003c\/p\u003e\n\n\u003cp\u003e133.\tKyowa Kirin\u003c\/p\u003e\n\n\u003cp\u003e134.\tKythera Biopharma (acquired by Allergan)\u003c\/p\u003e\n\n\u003cp\u003e135.\tLa Jolla Pharmaceutical Company\u003c\/p\u003e\n\n\u003cp\u003e136.\tLeadiant Biosciences\u003c\/p\u003e\n\n\u003cp\u003e137.\tLexicon Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e138.\tLundbeck\u003c\/p\u003e\n\n\u003cp\u003e139.\tLupin\u003c\/p\u003e\n\n\u003cp\u003e140.\tMacroGenics\u003c\/p\u003e\n\n\u003cp\u003e141.\tMaeda Industry\u003c\/p\u003e\n\n\u003cp\u003e142.\tMayne Pharma\u003c\/p\u003e \n\n\u003cp\u003e143.\tMEDIPHARMAPLAN\u003c\/p\u003e\n\n\u003cp\u003e144.\tMedicines Development for Global Health (MDGH)\u003c\/p\u003e\n\n\u003cp\u003e145.\tMedXL\u003c\/p\u003e \n\n\u003cp\u003e146.\tMelinta Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e147.\tMerck\u003c\/p\u003e\n\n\u003cp\u003e148.\tMillennium Pharmaceuticals (acquired by Takeda)\u003c\/p\u003e\n\n\u003cp\u003e149.\tMiltenyi Biotec\u003c\/p\u003e\n\n\u003cp\u003e150.\tMitsubishi Tanabe Pharma\u003c\/p\u003e\n\n\u003cp\u003e151.\tMorphoSys\u003c\/p\u003e\n\n\u003cp\u003e152.\tMyovant Sciences\u003c\/p\u003e\n\n\u003cp\u003e153.\tMystic Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e154.\tNabriva Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e155.\tNeurocrine Biosciences\u003c\/p\u003e\n\n\u003cp\u003e156.\tNipro\u003c\/p\u003e\n\n\u003cp\u003e157.\tNovartis\u003c\/p\u003e\n\n\u003cp\u003e158.\tNovimmune\u003c\/p\u003e\n\n\u003cp\u003e159.\tNovo Nordisk\u003c\/p\u003e\n\n\u003cp\u003e160.\tNPS Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e161.\tNS Pharma\u003c\/p\u003e\n\n\u003cp\u003e162.\tNündel Kunststofftechnologie\u003c\/p\u003e\n\n\u003cp\u003e163.\tOcular Therapeutix\u003c\/p\u003e\n\n\u003cp\u003e164.\tOncopeptides\u003c\/p\u003e\n\n\u003cp\u003e165.\tOrganon International\u003c\/p\u003e\n\n\u003cp\u003e166.\tOrigin Biosciences\u003c\/p\u003e\n\n\u003cp\u003e167.\tOrtho Dermatologics\u003c\/p\u003e\n\n\u003cp\u003e168.\tOtsuka Pharmaceutical\u003c\/p\u003e\n\n\u003cp\u003e169.\tPaladin\u003c\/p\u003e\n\n\u003cp\u003e170.\tParatek Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e171.\tPfizer\u003c\/p\u003e\n\n\u003cp\u003e172.\tPHC Injection Device Technologies\u003c\/p\u003e\n\n\u003cp\u003e173.\tPiramal Imaging\u003c\/p\u003e\n\n\u003cp\u003e174.\tPortola Pharmaceuticals (acquired by Alexion Pharmaceuticals)\u003c\/p\u003e\n\n\u003cp\u003e175.\tProgenics Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e176.\tPTC Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e177.\tPuma Biotechnology\u003c\/p\u003e\n\n\u003cp\u003e178.\tQED Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e179.\tRadius Health\u003c\/p\u003e\n\n\u003cp\u003e180.\tRecon Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e181.\tRecordati Rare Diseases\u003c\/p\u003e\n\n\u003cp\u003e182.\tRegeneron Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e183.\tRelypsa\u003c\/p\u003e\n\n\u003cp\u003e184.\tRempex Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e185.\tTravere Therapeutics (formerly Retrophin)\u003c\/p\u003e\n\n\u003cp\u003e186.\tRhythm Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e187.\tRidgeback Biotherapeutics\u003c\/p\u003e\n\n\u003cp\u003e188.\tRigel Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e189.\tRoche\u003c\/p\u003e\n\n\u003cp\u003e190.\tSage Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e191.\tSagentia Innovation\u003c\/p\u003e\n\n\u003cp\u003e192.\tSanofi\u003c\/p\u003e\n\n\u003cp\u003e193.\tSanofi Genzyme\u003c\/p\u003e\n\n\u003cp\u003e194.\tSarepta Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e195.\tSCHOTT\u003c\/p\u003e\n\n\u003cp\u003e196.\tSCHOTT-KAISHA\u003c\/p\u003e\n\n\u003cp\u003e197.\tSCYNEXIS\u003c\/p\u003e\n\n\u003cp\u003e198.\tSeagen\u003c\/p\u003e\n\n\u003cp\u003e199.\tServier Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e200.\tsfm medical devices\u003c\/p\u003e\n\n\u003cp\u003e201.\tShandong Pharmaceutical Glass\u003c\/p\u003e\n\n\u003cp\u003e202.\tShield Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e203.\tShionogi\u003c\/p\u003e\n\n\u003cp\u003e204.\tShire Pharmaceuticals (acquired by Takeda)\u003c\/p\u003e\n\n\u003cp\u003e205.\tSIGA Technologies\u003c\/p\u003e\n\n\u003cp\u003e206.\tSimplivia\u003c\/p\u003e\n\n\u003cp\u003e207.\tSIPPEX\u003c\/p\u003e\n\n\u003cp\u003e208.\tSK Life Science\u003c\/p\u003e\n\n\u003cp\u003e209.\tSKINSORB\u003c\/p\u003e\n\n\u003cp\u003e210.\tSpark Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e211.\tSpectrum Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e212.\tSprout Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e213.\tStemline Therapeutics (acquired by Menarini)\u003c\/p\u003e\n\n\u003cp\u003e214.\tStevanato Group\u003c\/p\u003e\n\n\u003cp\u003e215.\tStrongbridge Biopharma\u003c\/p\u003e\n\n\u003cp\u003e216.\tSun Pharma\u003c\/p\u003e\n\n\u003cp\u003e217.\tSun Pharma Advanced Research Company (SPARC)\u003c\/p\u003e\n\n\u003cp\u003e218.\tSupernus Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e219.\tSYMATESE DEVICE\u003c\/p\u003e\n\n\u003cp\u003e220.\tSynergy Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e221.\tTaian Youlyy Industrial\u003c\/p\u003e\n\n\u003cp\u003e222.\tTaiho Oncology\u003c\/p\u003e\n\n\u003cp\u003e223.\tTaiMed Biologics\u003c\/p\u003e\n\n\u003cp\u003e224.\tTaisei Kako\u003c\/p\u003e\n\n\u003cp\u003e225.\tTakeda Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e226.\tTechnoflex\u003c\/p\u003e\n\n\u003cp\u003e227.\tTerumo\u003c\/p\u003e\n\n\u003cp\u003e228.\tTESARO (acquired by GlaxoSmithKline)\u003c\/p\u003e\n\n\u003cp\u003e229.\tTetraphase Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e230.\tTeva Pharmaceutical\u003c\/p\u003e \n\n\u003cp\u003e231.\tTG Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e232.\tThe Conference Forum\u003c\/p\u003e\n\n\u003cp\u003e233.\tThe Feinstein Institutes for Medical Research\u003c\/p\u003e \n\n\u003cp\u003e234.\tThe International Research Conference\u003c\/p\u003e\n\n\u003cp\u003e235.\tThe Medicines Company (acquired by Novartis)\u003c\/p\u003e\n\n\u003cp\u003e236.\tThe Metrix Company (formerly Riggs BioChemical)\u003c\/p\u003e\n\n\u003cp\u003e237.\tTherapeuticsMD\u003c\/p\u003e\n\n\u003cp\u003e238.\tTheravance Biopharma and Mylan\u003c\/p\u003e\n\n\u003cp\u003e239.\tTrevena\u003c\/p\u003e\n\n\u003cp\u003e240.\tTyfill Pharmapack\u003c\/p\u003e\n\n\u003cp\u003e241.\tU.S. Food and Drug Administration (USFDA)\u003c\/p\u003e\n\n\u003cp\u003e242.\tUIHC – P E T Imaging Center\u003c\/p\u003e\n\n\u003cp\u003e243.\tUltragenyx Pharmaceutical\u003c\/p\u003e\n\n\u003cp\u003e244.\tUnilife\u003c\/p\u003e\n\n\u003cp\u003e245.\tUCB\u003c\/p\u003e\n\n\u003cp\u003e246.\tUnited Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e247.\tUnitract Syringe\u003c\/p\u003e\n\n\u003cp\u003e248.\tUniversity of California, Los Angeles (UCLA)\u003c\/p\u003e\n\n\u003cp\u003e249.\tUrovant Sciences\u003c\/p\u003e\n\n\u003cp\u003e250.\tUS WorldMeds\u003c\/p\u003e\n\n\u003cp\u003e251.\tValmed Pharma\u003c\/p\u003e\n\n\u003cp\u003e252.\tVANDA Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e253.\tVanrx Pharmasystems\u003c\/p\u003e\n\n\u003cp\u003e254.\tVerastem Oncology\u003c\/p\u003e\n\n\u003cp\u003e255.\tVericel\u003c\/p\u003e\n\n\u003cp\u003e256.\tVertex Pharmaceuticals\u003c\/p\u003e\n\n\u003cp\u003e257.\tVetter Pharma\u003c\/p\u003e\n\n\u003cp\u003e258.\tViela Bio (acquired by Horizon Therapeutics)\u003c\/p\u003e\n\n\u003cp\u003e259.\tViiV Healthcare\u003c\/p\u003e\n\n\u003cp\u003e260.\tVonlanthen\u003c\/p\u003e\n\n\u003cp\u003e261.\tVygon\u003c\/p\u003e\n\n\u003cp\u003e262.\tWeibel CDS\u003c\/p\u003e\n\n\u003cp\u003e263.\tWellstat Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e264.\tWest Pharmaceutical Services\u003c\/p\u003e\n\n\u003cp\u003e265.\tWyeth\u003c\/p\u003e\n\n\u003cp\u003e266.\tY-mAbs Therapeutics\u003c\/p\u003e\n\n\u003cp\u003e267.\tYpsomed\u003c\/p\u003e\n\n\u003cp\u003e268.\tYukon Medical\u003c\/p\u003e\n\n\u003cp\u003e269.\tZealand Pharma\u003c\/p\u003e\n\n\u003cp\u003e270.\tZionexa (acquired by GE Healthcare)\u003c\/p\u003e\n\n\n\n\u003cp\u003ePlease note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.\u003c\/p\u003e","brand":"Heavy Industry","offers":[{"title":"August, 2023 \/ 325 Pages \/ MCW16217307","offer_id":47619940385074,"sku":null,"price":5759.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/novel-drug-reconstitution-systems-market-2021-2030-distribution-by-type-of-container-cartridge-infusion-bag-and-prefilled-syringe-fabrication-material-glass-and-plastic-physical-state-of-drug-in-syringe-and-cartridge-liquid-powder-liquid-liq","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}